Citation & Authors
Diabetes Res Clin Pract. 2025;223:112174.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance study evaluated liver outcomes in patients with diabetes after excluding viral hepatitis and alcohol-related disease. Over a mean follow-up of approximately 2.7 years, SGLT2 inhibitor use was associated with lower risks of cirrhosis (aHR 0.78; 95% CI 0.70–0.87), decompensation, hepatic failure, and all-cause mortality. Some favorable associations were also observed in comparisons with other glucose-lowering drugs, although treatment-selection differences must be considered.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
